<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JCO Precis Oncol</journal-id><journal-id journal-id-type="iso-abbrev">JCO Precis Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">3882</journal-id><journal-id journal-id-type="pmc-domain">jcopo</journal-id><journal-id journal-id-type="publisher-id">PO</journal-id><journal-title-group><journal-title>JCO Precision Oncology</journal-title></journal-title-group><issn pub-type="epub">2473-4284</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10681426</article-id><article-id pub-id-type="pmcid-ver">PMC10681426.1</article-id><article-id pub-id-type="pmcaid">10681426</article-id><article-id pub-id-type="pmcaiid">10681426</article-id><article-id pub-id-type="pmid">37992259</article-id><article-id pub-id-type="doi">10.1200/PO.23.00091</article-id><article-id pub-id-type="publisher-id">PO.23.00091</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Precision Medicine</subject></subj-group></subj-group></article-categories><title-group><article-title>Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic>, Germline <italic toggle="yes">PALB2</italic>, or Homologous Recombination Deficiency Signature</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3354-308X</contrib-id><name name-style="western"><surname>Batalini</surname><given-names initials="F">Felipe</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><xref rid="con1" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7838-2526</contrib-id><name name-style="western"><surname>Madison</surname><given-names initials="RW">Russell W.</given-names></name><degrees>MA, BA</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con2" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2988-0537</contrib-id><name name-style="western"><surname>Sokol</surname><given-names initials="ES">Ethan S.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con3" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6545-1580</contrib-id><name name-style="western"><surname>Jin</surname><given-names initials="DX">Dexter X.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con4" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="KT">Kuei-Ting</given-names></name><degrees>MS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con5" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4516-7421</contrib-id><name name-style="western"><surname>Decker</surname><given-names initials="B">Brennan</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con6" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6075-6246</contrib-id><name name-style="western"><surname>Pavlick</surname><given-names initials="DC">Dean C.</given-names></name><degrees>BS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con7" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2361-2750</contrib-id><name name-style="western"><surname>Frampton</surname><given-names initials="GM">Garrett M.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con8" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7868-6231</contrib-id><name name-style="western"><surname>Wulf</surname><given-names initials="GM">Gerburg M.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="con9" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9449-3982</contrib-id><name name-style="western"><surname>Garber</surname><given-names initials="JE">Judy E.</given-names></name><degrees>MD, MPH</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="con10" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1054-8240</contrib-id><name name-style="western"><surname>Oxnard</surname><given-names initials="G">Geoffrey</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con11" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0106-9096</contrib-id><name name-style="western"><surname>Schrock</surname><given-names initials="AB">Alexa B.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con12" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1422-3734</contrib-id><name name-style="western"><surname>Tung</surname><given-names initials="NM">Nadine M.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="con13" ref-type="fn"/></contrib><aff id="aff1"><label><sup>1</sup></label>Mayo Clinic, Phoenix, AZ</aff><aff id="aff2"><label><sup>2</sup></label>Foundation Medicine, Inc, Boston, MA</aff><aff id="aff3"><label><sup>3</sup></label>Beth Israel Deaconess Medical Center, Boston, MA</aff><aff id="aff4"><label><sup>4</sup></label>Dana Farber Cancer Institute, Boston, MA</aff></contrib-group><author-notes><corresp id="cor1">Felipe Batalini, MD, Mayo Clinic, 5881 E Mayo Blvd, Phoenix, AZ 85054; e-mail: <email>Batalini.Felipe@mayo.edu</email>.</corresp></author-notes><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2023</year></pub-date><volume>7</volume><issue-id pub-id-type="pmc-issue-id">429012</issue-id><elocation-id>e2300091</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>5</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>13</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>22</day><month>11</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-29 20:25:37.060"><day>29</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by American Society of Clinical Oncology</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="po-7-e2300091.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="po-7-e2300091.pdf"/><abstract><sec><title>PURPOSE</title><p>Poly ADP-ribose polymerase inhibitors (PARPi) are approved for patients with human epidermal growth factor receptor 2&#8211;negative metastatic breast cancer (mBC) and germline pathogenic/likely pathogenic variant (hereafter mutation) in the <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> genes (g<italic toggle="yes">BRCA</italic>); however, clinical benefit has also been demonstrated in mBC with somatic <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> mutations (s<italic toggle="yes">BRCA</italic>) or germline <italic toggle="yes">PALB2</italic> mutations (g<italic toggle="yes">PALB2</italic>). This study aims to describe the genomic landscape of homologous recombination repair (HRR) gene alterations in mBC and assess PARPi treatment outcomes for patients with g<italic toggle="yes">BRCA</italic> compared with other HRR genes and by status of a novel homologous recombination deficiency signature (HRDsig).</p></sec><sec><title>METHODS</title><p>A real-world (RW) clinico-genomic database (CGDB) of comprehensive genomic profiling (CGP) linked to deidentified, electronic health record&#8211;derived clinical data was used. CGP was analyzed for HRR genes and HRDsig. The CGDB enabled cohort characterization and outcomes analyses of 177 patients exposed to PARPi. RW progression-free survival (rwPFS) and RW overall survival (rwOS) were compared.</p></sec><sec><title>RESULTS</title><p>Of 28,920 patients with mBC, g<italic toggle="yes">BRCA</italic> was detected in 3.4%, whereas the population with any <italic toggle="yes">BRCA</italic> alteration or g<italic toggle="yes">PALB2</italic> increased to 9.5%. HRDsig+ represented 21% of patients with mBC. <italic toggle="yes">BRCA</italic> and g<italic toggle="yes">PALB2</italic> had higher levels of biallelic loss and HRDsig+ than other HRR alterations. Outcomes on PARPi were assessed for 177 patients, and g<italic toggle="yes">BRCA</italic> and s<italic toggle="yes">BRCA</italic>/<italic toggle="yes">gPALB2</italic> cohorts were similar: g<italic toggle="yes">BRCA</italic> versus s<italic toggle="yes">BRCA</italic>/g<italic toggle="yes">PALB2</italic> rwPFS was 6.3 versus 5.4 months (hazard ratio [HR], 1.37 [0.77-2.43]); rwOS was 16.2 versus 21.2 months (HR, 1.45 [0.74-2.86]). Additionally, patients with HRDsig+ versus HRDsig&#8211; had longer rwPFS (6.3 <italic toggle="yes">v</italic> 2.8 months; HR, 0.62 [0.42-0.92]) and numerically longer rwOS (17.8 <italic toggle="yes">v</italic> 13.0 months; HR, 0.72 [0.46-1.14]).</p></sec><sec><title>CONCLUSION</title><p>Patients with s<italic toggle="yes">BRCA</italic> and g<italic toggle="yes">PALB2</italic> derive similar benefit from PARPi as those with g<italic toggle="yes">BRCA</italic> alterations. In combination, HRDsig+, s<italic toggle="yes">BRCA</italic>, and g<italic toggle="yes">PALB2</italic> represent an additional 19% of mBC that can potentially benefit from PARPi. Randomized trials exploring a more inclusive biomarker such as HRDsig are warranted.</p></sec></abstract><abstract abstract-type="teaser"><p>This is real-world evidence supporting benefit of PARPi in sBRCA, gPALB2, and HRDsig.</p></abstract><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="29"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>INTRODUCTION</title><p>Poly ADP-ribose polymerase inhibitors (PARPi) are small molecules that cause synthetic lethality in tumors with homologous recombination deficiency (HRD).<sup><xref rid="b1" ref-type="bibr">1</xref></sup> Although PARPi were not effective in the treatment of unselected and heavily pretreated patients with metastatic triple-negative breast cancer (TNBC),<sup><xref rid="b2" ref-type="bibr">2</xref></sup> olaparib and talazoparib are beneficial to those with a germline <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> (g<italic toggle="yes">BRCA</italic>) pathogenic or likely pathogenic variant (hereafter mutation; aka g<italic toggle="yes">BRCA</italic> carriers).<sup><xref rid="b3" ref-type="bibr">3</xref>-<xref rid="b5" ref-type="bibr">5</xref></sup></p><boxed-text id="B1" position="anchor" orientation="portrait"><sec sec-type="context-box"><title>CONTEXT</title><p>
<list list-type="simple"><list-item><p>
<bold>Key Objective</bold>
</p></list-item><list-item><p>Poly ADP-ribose polymerase inhibitors (PARPi) are approved for the treatment of breast cancers in patients with a germline pathogenic variant in the <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> genes (g<italic toggle="yes">BRCA</italic>), which represents only a small fraction of all patients with breast cancer. We sought to quantify the frequency of alterations across homologous recombination repair-genes, the prevalence of homologous recombination deficiency signature (HRDsig), and compare outcomes with PARPi on the basis of these biomarkers.</p></list-item><list-item><p>
<bold>Knowledge Generated</bold>
</p></list-item><list-item><p>Among patients with breast cancer, the frequency of each individual gene alteration is low but the population with HRDsig is large. Compared with g<italic toggle="yes">BRCA</italic>, patients with s<italic toggle="yes">BRCA</italic> and g<italic toggle="yes">PALB2</italic> have similar benefit from PARPi and HRDsig+ tumors have longer progression-free survival than HRDsig&#8211; tumors.</p></list-item><list-item><p>
<bold>Relevance</bold>
</p></list-item><list-item><p>We present real-world evidence supporting the findings of single-arm phase II studies revealing benefit of PARPi in s<italic toggle="yes">BRCA</italic> and g<italic toggle="yes">PALB2.</italic> Further, we demonstrate that HRDsig could be used to identify a much larger population of breast cancer patients who may benefit from PARPi.</p></list-item></list>
</p></sec></boxed-text><p>In some tumor types (ie, breast and pancreatic cancers), PARPi are approved only for g<italic toggle="yes">BRCA</italic> carriers, and others (ie, prostate and ovarian cancers) have more inclusive criteria beyond g<italic toggle="yes">BRCA</italic>. For prostate cancer, olaparib and rucaparib are approved for patients with alterations (germline or somatic) in any of 14 homologous recombination repair (HRR) genes. For ovarian cancer, benefit with PARPi has been observed in patients with g<italic toggle="yes">BRCA</italic> and s<italic toggle="yes">BRCA</italic> mutations,<sup><xref rid="b6" ref-type="bibr">6</xref></sup> as well as those with elevated tumor genomic instability score (GIS), genome-wide loss-of-heterozygosity, and in some patients with advanced disease and no HRD biomarkers, although the degree of benefit in HRD-negative tumors is modest.<sup><xref rid="b6" ref-type="bibr">6</xref>-<xref rid="b10" ref-type="bibr">10</xref></sup> To identify patients with metastatic breast cancer (mBC) beyond those with g<italic toggle="yes">BRCA</italic> mutations who may benefit from PARPi, TBCRC-048 (the Olaparib Expanded trial) evaluated olaparib in gBRCA-negative patients with a germline or somatic mutation in an HRR pathway gene, and reported an 80% response rate in patients with g<italic toggle="yes">PALB2</italic> mutations and a 50% in those with somatic <italic toggle="yes">BRCA</italic> (s<italic toggle="yes">BRCA</italic>) mutations. Evaluation in larger cohorts to confirm these results are ongoing.<sup><xref rid="b11" ref-type="bibr">11</xref></sup></p><p>TBCRC-048 highlighted the difficulty in studying the predictive effect of rare gene alterations. Thus, a unifying genomic biomarker of HRD could be useful to further identify patients who might benefit from PARPi. HRD signature (HRDsig) is a novel genomic scar&#8211;based algorithm that has been shown to predict PARPi response for HRD tumors.<sup><xref rid="b12" ref-type="bibr">12</xref></sup></p><p>We analyzed 28,920 mBC cases and evaluated variant characteristics, germline status, allelic status, and HRDsig, with a focus on HRR and cancer predisposition genes. Using a real-world (RW) clinico-genomic database (CGDB), we explored characteristics and outcomes for a subset of patients to identify those likely to benefit from PARPi.</p><p>The primary aims of this study were to compare outcomes in patients with g<italic toggle="yes">PALB2</italic> or s<italic toggle="yes">BRCA</italic> mutations compared with patients with g<italic toggle="yes">BRCA</italic> mutations treated with PARPi. In addition, we compared outcomes between patients whose tumors had an HRDsig (HRDsig+) with those whose did not (HRDsig&#8211;).</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Comprehensive Genomic Profiling</title><p>Twenty-eight thousand nine hundred twenty consecutive centrally reviewed breast carcinomas underwent comprehensive genomic profiling (CGP) in a Clinical Laboratory Improvements Act-College of American Pathologists, New York State&#8211;regulated reference laboratory (Foundation Medicine, Inc, Cambridge, MA), as previously described.<sup><xref rid="b13" ref-type="bibr">13</xref></sup> Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from WCG institutional review board (protocol No. 20152817). Further details are provided in the Data Supplement (Methods S1).</p></sec><sec><title>Somatic and Germline Variant Determination</title><p>Recurrent predicted benign germline variants were excluded from all analyses; allelic status and somatic/germline status for mutations were computationally predicted without matched normal tissue with the accuracy of 95% for somatic and 99% for germline.<sup><xref rid="b14" ref-type="bibr">14</xref></sup> HRR gene alteration allelic status was categorized as biallelic, monoallelic, or unknown as described previously.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> Further details are provided in the Data Supplement (Methods S1).</p></sec><sec><title>Homologous Recombination Deficiency Biomarkers</title><p>HRR genes (Data Supplement, Table S1) were defined by the inclusion criteria for the TBCRC-048 trial.<sup><xref rid="b11" ref-type="bibr">11</xref></sup> HRDsig was called using a machine learning&#8211;based algorithm.<sup><xref rid="b12" ref-type="bibr">12</xref></sup> Briefly, copy-number features and select indel features&#8212;as defined by Alexandrov et al<sup><xref rid="b16" ref-type="bibr">16</xref></sup>&#8212;were extracted from segmented copy-number profiles and used as inputs into an extreme gradient boosting machine learning model. Training data labels were defined as biallelic <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> for true positives and HRR wild-type (WT for <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">ATM</italic>, <italic toggle="yes">BARD1</italic>, <italic toggle="yes">BRIP1</italic>, <italic toggle="yes">CDK12</italic>, <italic toggle="yes">CHEK1</italic>, <italic toggle="yes">CHEK2</italic>, <italic toggle="yes">FANCL</italic>, <italic toggle="yes">PALB2</italic>, <italic toggle="yes">RAD51B</italic>, <italic toggle="yes">RAD51C</italic>, <italic toggle="yes">RAD51D</italic>, and <italic toggle="yes">RAD54L</italic> alterations) for true negatives. A simulated GIS was calculated from segmented copy-number profiles and represented a sum of qualifying loss of heterozygosity segments,<sup><xref rid="b17" ref-type="bibr">17</xref></sup> telomeric allelic imbalance (TAI) events,<sup><xref rid="b18" ref-type="bibr">18</xref></sup> and large-scale transition (LST) adjusted for ploidy<sup><xref rid="b19" ref-type="bibr">19</xref></sup> by subtracting 15.5 &#215; ploidy as previously described,<sup><xref rid="b20" ref-type="bibr">20</xref></sup> and the established cutoff of 42 was used to classify patients as GIS+.<sup><xref rid="b20" ref-type="bibr">20</xref></sup> Herein, we refer to GIS rather than HRD score because we calculated only the GIS component, whereas the Myriad MyChoice CDx HRD score&#8212;not used in this manuscript&#8212;is considered positive if either GIS is high (&#8805;42) or a <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> mutation is present. Moreover, we advocate that HRD score is a more general term, and GIS is more specific to the score that incorporates LOH, LST, and TAI.</p></sec><sec sec-type="subjects"><title>Patient Selection and Outcomes Analysis</title><p>Clinical analyses for a subset of patients included in the genomic landscape analysis used the nationwide (US-based) deidentified Flatiron Health-Foundation Medicine breast cancer CGDB (FH-FMI CGDB). The deidentified data originated from approximately 280 US cancer clinics (approximately 800 sites of care). Retrospective longitudinal clinical data were derived from electronic health records, comprising patient-level structured and unstructured data, curated via technology-enabled abstraction of clinical notes and radiology/pathology reports, which were linked to genomic data derived from FMI testing by deidentified, deterministic matching.<sup><xref rid="b21" ref-type="bibr">21</xref></sup></p><p>The FH-FMI CGDB included 11,773 patients diagnosed with breast cancer from January 2011 to March 2022 who underwent FMI CGP. We selected unique patients who met the following inclusion criteria: (1) a confirmed visit in the FH network within 90 days of metastatic diagnosis, (2) an FMI tissue CGP result, (3) 60 days or less between last FH network visit and CGP result, (4) PARPi treatment after CGP specimen collection, (5) documented assessment of RW progression (rwP), and (6) entrance to at-risk population before rwP or relevant censor date. Patients were grouped according to the presence of germline or somatic mutations in <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> and g<italic toggle="yes">PALB2</italic>. Additionally, HRDsig was used to classify tumors as HRDsig+ or HRDsig&#8211; (Fig <xref rid="fig1" ref-type="fig">1</xref>). Since patients with other HRR gene mutations (eg, <italic toggle="yes">ATM</italic> and <italic toggle="yes">CHEK2</italic>) have been found to not respond to PARPi, and the responsiveness of tumors with mutations in other HRR genes (eg, <italic toggle="yes">RAD51C</italic>/<italic toggle="yes">D</italic>) has not been determined in breast cancer,<sup><xref rid="b11" ref-type="bibr">11</xref></sup> patients without <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> or g<italic toggle="yes">PALB2</italic> mutations were compared based on the HRDsig status.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>FIG 1.</label><caption><p>Patient data were analyzed from two databases. FMI's genomic data set was leveraged to explore the landscape of HRR alterations and HRDsig in breast carcinoma and the FH-FMI CGDB was used to assess outcomes to PARPi. CGP, comprehensive genomic profiling; FH-FMI CGDB, Flatiron Health-Foundation Medicine breast cancer clinico-genomic database; gLOH, genome-wide loss-of-heterozygosity; HRDsig, homologous recombination deficiency signature; HRR, homologous recombination repair; PARPi, poly ADP-ribose polymerase inhibitors; SGZ, somatic germline zygosity; WT, wild-type.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g001.jpg"/></fig><p>rwP, RW progression-free survival (rwPFS), and RW overall survival (rwOS) definition events are described in detail in the Data Supplement (Methods S1).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>HRR Gene Alteration Landscape</title><p><italic toggle="yes">BRCA1</italic>/2-predicted inactivating alterations were detected in 8.9% (n = 2,571) of cases, with <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> alterations accounting for 3.9% (n = 1,126) and 4.9% (n = 1,412), respectively, whereas 0.1% (n = 33) harbored alterations in both genes. <italic toggle="yes">PALB2</italic> alterations were observed in 1.4% (n = 412) of breast cancer cases. <italic toggle="yes">BRCA2</italic> short coding mutations and indels (muts/indels) were the most frequently detected HRR alteration (4.3%, n = 1,217), and computational assessment classified 49% as germline (n = 594), 30% as somatic (n = 365), and 21% as unknown (n = 256). <italic toggle="yes">BRCA1</italic> muts/indels were detected in 3.2% of cases (n = 908) and 43% were classified as germline (n = 386), 32% as somatic (n = 289), and 25% as unknown (n = 225). <italic toggle="yes">PALB2</italic> muts/indels (n = 371) consisted of 51% germline (n = 188), 26% somatic (n = 97), and 22% unknown (n = 81) alterations. Homozygous deletions (<italic toggle="yes">BRCA2</italic>, n = 136; <italic toggle="yes">BRCA1</italic>, n = 101; <italic toggle="yes">PALB2</italic>, n <italic toggle="yes">=</italic> 9) and genomic rearrangements (<italic toggle="yes">BRCA2</italic>, n = 118; <italic toggle="yes">BRCA1</italic>, n = 178; <italic toggle="yes">PALB2</italic>, n = 37) were relatively uncommon compared with muts/indels, and somatic and germline predictions were not available for these alteration classes (Fig <xref rid="fig2" ref-type="fig">2</xref>A). Other commonly altered HRR genes included <italic toggle="yes">ATM</italic> (2.8%, n = 801) and <italic toggle="yes">CHEK2</italic> (2.4%, n = 683; Fig <xref rid="fig2" ref-type="fig">2</xref>A). Biallelic inactivation was observed in more than 70% of tumors with g<italic toggle="yes">BRCA</italic>, s<italic toggle="yes">BRCA</italic>, and g<italic toggle="yes">PALB2</italic> mutations and in fewer than 40% of tumors with s<italic toggle="yes">PALB2</italic> and other HRR mutations (Fig <xref rid="fig2" ref-type="fig">2</xref>B).</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>FIG 2.</label><caption><p>(A) In addition to <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> germline mutations, a diverse landscape of somatic and germline mutations, along with copy-number loss and genomic rearrangements, are detected in genes associated with homologous recombination. For cases with multiple alterations in the same gene, alteration type is prioritized in the following order: (1) germline mut/indel, somatic mut/indel, unknown mut/indel, homozygous deletion, and rearrangement. (B) Biallelic inactivation is necessary to induce HRD. Biallelic inactivation is commonly observed in all <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> short coding variants (mut/indel) and cases with <italic toggle="yes">PALB2</italic> germline mut/indel. Cases with multiple alterations in a single gene were considered biallelic, and if at least one mutation was germline, the case was classified as germline. (C) HRDsig within <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, and other HRR pathogenic and likely pathogenic variants compared by germline/somatic status. (D) HRDsig within <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, and other HRR pathogenic and likely pathogenic variants compared by biallelic/monoallelic status. (E) Frequency of HRDsig within HRR WT tumors, tumors harboring other HRR alterations (including <italic toggle="yes">sPALB2</italic>), or BRCA/gPALB2 alterations. For outer ring, percentages in parenthesis represent percent of full cohort. HRDsig, homologous recombination deficiency signature; HRR, homologous recombination repair; WT, wild-type.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g002.jpg"/></fig><p>Clinical and genomic features were compared according to g<italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic>, s<italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic>, and g<italic toggle="yes">PALB2</italic> status (Table <xref rid="tbl1" ref-type="table">1</xref>; Data Supplement, Table S2). Overall, no notable differences in breast cancer subtypes or sex were seen, but patients with g<italic toggle="yes">BRCA</italic> or g<italic toggle="yes">PALB2</italic> tumors had a lower median age than their somatic counterparts, as expected.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE 1.</label><caption><p>Clinical and Genomic Characteristics for Those Patients Whose Tumors Were Classified as g<italic toggle="yes">BRCA</italic>, s<italic toggle="yes">BRCA</italic>, or g<italic toggle="yes">PALB2</italic></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g003.jpg"/></table-wrap><p>Similar to biallelic inactivation, high rates of HRDsig positivity (HRDsig+) were seen in g<italic toggle="yes">BRCA-</italic>mutated (88%), s<italic toggle="yes">BRCA-</italic>mutated (76%), and g<italic toggle="yes">PALB2-</italic>mutated (77%) tumors, suggesting that all three mutation classes commonly result in functional HRD (Fig <xref rid="fig2" ref-type="fig">2</xref>C). In addition, 70% of tumors with <italic toggle="yes">BRCA</italic> mutations of unknown origin (germline or somatic) also had high frequency of HRDsig+, whereas only 52% of <italic toggle="yes">sPALB2-</italic>mutated were HRDsig+, mirroring the lower rate of biallelic inactivation in these cases. Other germline and somatic HRR-mutated had substantially lower rates of HRDsig+ (both 17%; Fig <xref rid="fig2" ref-type="fig">2</xref>C). Given the association of germline alterations with both allelic status and HRDsig, we investigated the association between allelic status and HRDsig for <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, and other HRR alterations (somatic, germline, or unknown). We found a strong association between HRDsig+ and biallelic inactivation for <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">PALB2</italic> alterations (93%, 91%, and 93%, respectively) compared with specimens with monoallelic inactivation (47%, 23%, and 28%, respectively). Similar to allelic status and germline status, the association between biallelic inactivation in other HRR genes and HRDsig was marginal (21% <italic toggle="yes">v</italic> 15%; Fig <xref rid="fig2" ref-type="fig">2</xref>D), and even when both alleles of these genes were inactivated, they were typically HRDsig&#8211;. Details for specific gene alterations are provided in the Data Supplement (Table S3).</p><p>Overall, of 28,920 mBCs, predicted g<italic toggle="yes">BRCA</italic> alterations were detected in 3% (n = 980/28,920). The group of s<italic toggle="yes">BRCA</italic>/unk<italic toggle="yes">BRCA</italic>/<italic toggle="yes">gPALB2</italic> patients comprised an additional 6% (n = 1,774/28,920). HRDsig+ was observed in 21% of mBC cases (6,041/28,920), including 78% (2,156/2,754) of specimens with <italic toggle="yes">BRCA</italic> or <italic toggle="yes">gPALB2</italic> alterations, 21% (721/3,493) with other HRR alterations, and 14% (3,164/22,673) with HRR WT (Fig <xref rid="fig2" ref-type="fig">2</xref>E).</p></sec><sec><title>Outcomes on PARPi Stratified by Gene and Mutation Origin</title><p>A total of 177 patients treated with PARPi were included in the CGDB and met inclusion criteria (Fig <xref rid="fig1" ref-type="fig">1</xref>). Patients were grouped according to genomic alterations and included patients with g<italic toggle="yes">BRCA</italic> (for which PARPi are already approved) and patients with s<italic toggle="yes">BRCA</italic> or g<italic toggle="yes">PALB2</italic> (s<italic toggle="yes">BRCA</italic>/<italic toggle="yes">gPALB2</italic>). Within the 177 patients, there were <italic toggle="yes">gBRCA</italic> (n = 71), <italic toggle="yes">sBRCA</italic> (n = 23), and <italic toggle="yes">gPALB2</italic> (n = 8) on the basis of FMI tissue CGP results. The remaining patients (n = 75) were included in the assessment of outcomes using HRDsig. Prognostic factors such as hormone receptor status and histologic subtype were similar between the groups, whereas previous exposure to platinum chemotherapy was more common in patients with g<italic toggle="yes">BRCA</italic> mutations (g<italic toggle="yes">BRCA</italic> 30% <italic toggle="yes">v</italic> s<italic toggle="yes">BRCA</italic>/<italic toggle="yes">gPALB2</italic> 7%; <italic toggle="yes">P</italic> = .02). Additionally, patients with g<italic toggle="yes">BRCA</italic> tended to receive PARPi earlier (first/second line) during the treatment course of metastatic disease (30% <italic toggle="yes">v</italic> 23%; <italic toggle="yes">P</italic> = .05; Table <xref rid="tbl2" ref-type="table">2</xref>). Similar to the full genomics data set, both cohorts had high levels of biallelic inactivation of the relevant gene and HRDsig+ (Table <xref rid="tbl2" ref-type="table">2</xref>; Data Supplement, Fig S1). In the <italic toggle="yes">gBRCA</italic> cohort, only 1% (1/71) had predicted monoallelic inactivation and 77% (55/71) had confirmed <italic toggle="yes">BRCA</italic> biallelic inactivation (83% of <italic toggle="yes">BRCA1</italic> and 74% of <italic toggle="yes">BRCA2</italic>), whereas status was unknown in 20% (14/71). The s<italic toggle="yes">BRCA</italic>/<italic toggle="yes">gPALB2</italic> cohort had biallelic loss confirmed in 65% (16/23) for s<italic toggle="yes">BRCA</italic> and 75% (6/8) for g<italic toggle="yes">PALB2</italic>.</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>TABLE 2.</label><caption><p>Clinical and Genomic Characteristics at the Start of PARPi for Those Patients Whose Tumors Were Classified as g<italic toggle="yes">BRCA</italic> or s<italic toggle="yes">BRCA</italic>/g<italic toggle="yes">PALB2</italic></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g004.jpg"/></table-wrap><p>PARPi treatment outcomes, as assessed by rwPFS and rwOS, were similar for the g<italic toggle="yes">BRCA</italic> and s<italic toggle="yes">BRCA</italic>/g<italic toggle="yes">PALB2</italic> cohorts. The median rwPFS for g<italic toggle="yes">BRCA</italic> patients was 6.0 months (95% CI, 4.6 to 8.2) versus 5.4 months (3.6 to 8.6) for those with <italic toggle="yes">sBRCA</italic>/<italic toggle="yes">gPALB2</italic> tumors (hazard ratio [HR] <italic toggle="yes">gBRCA</italic> [ref], 1.56 [0.87-2.82]; Figs <xref rid="fig3" ref-type="fig">3</xref>A and <xref rid="fig3" ref-type="fig">3</xref>B). The median rwOS from the start of PARPi was also similar in the s<italic toggle="yes">BRCA</italic>/<italic toggle="yes">gPALB2</italic> compared with the g<italic toggle="yes">BRCA</italic> cohort (21.2 [14.2-NR] <italic toggle="yes">v</italic> 20.9 [13.7-33.8] months), and hazard of death (HR g<italic toggle="yes">BRCA</italic> [ref], 1.63 [0.82-3.24]) was not significantly different between the two groups when accounting for other clinical factors (Figs <xref rid="fig3" ref-type="fig">3</xref>C and <xref rid="fig3" ref-type="fig">3</xref>D). There were clinical factors that were associated with outcomes. Previous exposure to platinum chemotherapy was associated with increased hazard of progression (HR, 2.35 [1.22-4.51]), whereas ECOG &#8805;2 was associated with increased risk of death (3.09 [1.35-7.09]).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>FIG 3.</label><caption><p>Kaplan-Meier curves for (A) RW progression-free survival and (C) RW overall survival from the start of PARPi for patients with tumors classified as g<italic toggle="yes">BRCA</italic> or s<italic toggle="yes">BRCA</italic>/g<italic toggle="yes">PALB2</italic>. (B and D) Hazard ratios from multivariate Cox proportional hazards models. ECOG, Eastern Cooperative Oncology Group; ER+/PR+, estrogen receptor-positive or progesterone receptor-positive; HER2, human epidermal growth factor receptor 2; PARPi, poly ADP-ribose polymerase inhibitors; RW, real-world; TNBC, triple-negative breast cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g005.jpg"/></fig><p>Although the sample size was not well powered statistically, numerical comparison of rwPFS and rwOS for s<italic toggle="yes">BRCA</italic> patients (n = 24) and g<italic toggle="yes">PALB2</italic> patients (n = 8) did not reveal major differences: median rwPFS (s<italic toggle="yes">BRCA</italic>, 4.6 months [3.0-8.1]; g<italic toggle="yes">PALB2</italic>, 8.6 months [6.4-NR]) and median rwOS (s<italic toggle="yes">BRCA</italic>, 21.2 months [13.8-NR]; g<italic toggle="yes">PALB2</italic>, 19.0 months [14.2-NR]).</p><p>Additionally, we compared outcomes for patients with <italic toggle="yes">BRCA</italic> (g<italic toggle="yes">BRCA</italic>, s<italic toggle="yes">BRCA</italic>, or unknown <italic toggle="yes">BRCA</italic>) or g<italic toggle="yes">PALB2</italic> (n = 141) to patients with other HRR mutations (n = 16) or HRR WT tumors (n = 20). We saw significantly worse rwPFS and rwOS in the other HRR group (rwPFS, 1.9 [1.5-2.9] months; rwOS, 8.7 [3.7-NR] months) and for HRR WT (rwPFS, 2.5 [1.7-NR] months; rwOS, 13.9 [9.4-NR] months) compared with patients with <italic toggle="yes">BRCA</italic> or g<italic toggle="yes">PALB2</italic> (rwPFS, 6.3 [5.0-7.6] months; rwOS, 20.9 [14.1-23.8] months; Data Supplement, Fig S2).</p></sec><sec><title>Outcomes of PARPi on the Basis of HRDsig</title><p>We further stratified patients using HRDsig, rather than individual genes, and compared demographics and outcomes of PARPi therapy. Patients with HRDsig+ were enriched for poorer-prognosis TNBC (Table <xref rid="tbl3" ref-type="table">3</xref>). Nevertheless, patients with HRDsig+ had a significantly longer median rwPFS on PARPi compared with HRDsig&#8211; (5.9 <italic toggle="yes">v</italic> 3.0 months; HR HRDsig&#8211; [ref], 0.65 [0.43-0.96]; Figs <xref rid="fig4" ref-type="fig">4</xref>A and <xref rid="fig4" ref-type="fig">4</xref>B). The point estimate of rwOS of HRDsig+ patients was superior to HRDsig&#8211; (median, 18.4 <italic toggle="yes">v</italic> 13.0 months) but hazard of death (HR, 0.69 [0.43-1.12]) was not significantly different (Figs <xref rid="fig4" ref-type="fig">4</xref>C and <xref rid="fig4" ref-type="fig">4</xref>D). As in our analysis of patients with g<italic toggle="yes">BRCA</italic> versus s<italic toggle="yes">BRCA</italic>/g<italic toggle="yes">PALB2</italic>, previous platinum was associated with increased hazard of progression (HR, 2.47 [1.60-3.83]), but patients with TNBC had similar outcomes to those with other subtypes despite having higher rates of platinum exposure at the time of PARPi treatment (33% <italic toggle="yes">v</italic> 21%).</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>TABLE 3.</label><caption><p>Clinical and Genomic Characteristics at the Start of PARPi Stratified by HRDsig Status</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g006.jpg"/></table-wrap><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>FIG 4.</label><caption><p>Kaplan-Meier curves for (A) RW progression-free survival and (C) RW overall survival from the start of PARPi for stratified on HRDsig status. (B and D) Hazard ratios from multivariate Cox proportional hazards models. ECOG, Eastern Cooperative Oncology Group; ER+/PR+, estrogen receptor-positive or progesterone receptor-positive; HER2, human epidermal growth factor receptor 2; HRDsig, homologous recombination deficiency signature; PARPi, poly ADP-ribose polymerase inhibitors; RW, real-world; TNBC, triple-negative breast cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="po-7-e2300091-g007.jpg"/></fig><p>Given the utility of GIS in ovarian cancer, patient outcomes based off GIS were also explored. For both rwPFS (5.2 <italic toggle="yes">v</italic> 5.3 months; HR GIS&#8211; [ref], 1.00 [0.72-1.47]) and rwOS (19.5 <italic toggle="yes">v</italic> 14.1 months; HR GIS&#8211; [ref], 0.86 [0.57-1.30]), no significant differences were seen between the GIS+ and GIS&#8211; cohorts (Data Supplement, Fig S3). Given the difference in predictive value for patients with breast cancer treated with PARPi observed for HRDsig and GIS, we assessed the overlap between our simulated GIS and HRDsig in our large genomic database of breast cancer samples and found that although 14% of samples were positive for both, 7.0% were HRDsig+ but GIS&#8211; and 7.8% were HRDsig&#8211; but GIS+; the remaining 71% were negative for both. Among the HRDsig&#8211; cohort, the majority of samples had a GIS of &lt;42, but for the HRDsig+ cohort, approximately one third of samples had GIS &lt;42 (Data Supplement, Fig S4).</p><p>The duration of individual responses to PARPi for patients without <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic> or g<italic toggle="yes">PALB2</italic> mutations are shown in the Data Supplement (Fig S5), which includes patients with other HRR mutations/HRDsig+ (n = 8), other HRR alterations/HRDsig&#8211; (n = 11), HRR WT/HRDsig+ (n = 4), and HRR WT/HRDsig&#8211; (n = 13). Notably, there are patients, including several with HRR WT disease or biallelic mutations in <italic toggle="yes">ATM</italic> or <italic toggle="yes">BARD1</italic>, with long duration on therapy (&gt;6 months). However, several patients remained on therapy despite evidence of progressive disease, suggesting these patients may have had more indolent disease or exhausted other more cytotoxic regimens. Some of these responsive HRR WT cases are captured by HRDsig+ and some are not.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>These results suggest that the benefit of PARPi may extend beyond g<italic toggle="yes">BRCA</italic> carriers. Our results provide real-world evidence supporting outcomes from the TBCRC-048 trial and suggest that patients with mBC with s<italic toggle="yes">BRCA</italic> or g<italic toggle="yes">PALB2</italic> mutation may also benefit from PARPi. Another recent trial, Talazoparib Beyond <italic toggle="yes">BRCA</italic>, showed similar results for g<italic toggle="yes">PALB2</italic> and tumors positive for HRD as assessed by GIS.<sup><xref rid="b22" ref-type="bibr">22</xref></sup> In our study, high rates of biallelic inactivation and HRDsig+ were seen across patients with all three mutation types. Even in patients with <italic toggle="yes">BRCA</italic> alterations with unknown germline/somatic status, biallelic inactivation and HRDsig+ were common, indicating that any <italic toggle="yes">BRCA</italic> alteration can guide the selection of patients for PARPi irrespective of known germline or somatic origin. The similar rwPFS for patients with s<italic toggle="yes">BRCA</italic> or g<italic toggle="yes">PALB2</italic> alterations is encouraging and clinically meaningful. Most patients with mBC eventually progress on first-line chemotherapy. PARPi present an attractive alternative or subsequent treatment option, as they rarely cause alopecia and are associated with better quality of life.<sup><xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b23" ref-type="bibr">23</xref></sup></p><p>In our analysis, the inclusion of tumors with s<italic toggle="yes">BRCA</italic> or g<italic toggle="yes">PALB2</italic> mutations and those with HRDsig+ broadens the population of patients with mBC who could benefit from PARPi. Conversely, data supporting the role of alterations in other HRR genes, such as <italic toggle="yes">ATM</italic> and <italic toggle="yes">CHEK2</italic>, as predictors of response to PARPi for patients with mBC are still lacking. TBCRC-048 included 18 patients with germline or somatic mutations in <italic toggle="yes">ATM</italic> or <italic toggle="yes">CHEK2</italic>, none of whom achieved an objective response or stable disease for at least 6 months. It is still unclear whether the PARPi response will be restricted to pathogenic variants in specific genes, germline or somatic, and the search for biomarkers of response to PARPi is an area of active investigation.<sup><xref rid="b24" ref-type="bibr">24</xref>,<xref rid="b25" ref-type="bibr">25</xref></sup> Furthermore, a small number of patients without HRD biomarkers had &gt;6-month duration of response on PARPi, and in two cases, no documented progression after 6 months. It is possible that PARPi may influence immune-dependent response that is independent of HRD.<sup><xref rid="b26" ref-type="bibr">26</xref></sup></p><p>Scar-based functional readouts such as HRDsig are a promising avenue to address these clinical challenges. We examined the association of HRR alterations with a novel HRDsig. It is provocative that the cohorts that most benefited from PARPi in TBCRC-048 had the most tumors classified as HRDsig+; these results are consistent with previous studies on the basis of the detection of COSMIC single-base substitution mutational signature 3.<sup><xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref></sup> Importantly, we find that 21% of mBCs are classified as HRDsig+, and HRDsig+ was associated with improved rwPFS compared with HRDsig&#8211;. Lower rates of HRDsig+ seen in s<italic toggle="yes">PALB2</italic> and tumors with other HRR alterations suggest HRDsig+ can help avoid futile use of PARPi for patients with other HRR alterations not resulting in functional HRD. Consistent with these findings, van der Wijngaart et al<sup><xref rid="b29" ref-type="bibr">29</xref></sup> observed a high response rate in patients with biallelic <italic toggle="yes">BRCA</italic> inactivation across tumor types. We also note that in some cases, clinical benefit was observed in patients with tumors that were HRR WT but HRDsig+, underscoring that the currently approved biomarker, g<italic toggle="yes">BRCA</italic>, and even extension to s<italic toggle="yes">BRCA</italic> and g<italic toggle="yes">PALB2</italic>, may not fully capture all patients whose tumors have HRD.</p><p>A major strength of this study is that the large real-world genomic and clinicogenomic data sets enable the study of rare mutations, which are not with clinical trials. Limitations include that germline/somatic <italic toggle="yes">BRCA</italic> status and GIS were determined using computational predictions from tumor sequencing. The GIS reported was calculated based off published methods and not directly assessed using the CDx assay approved in ovarian cancer. There are also limitations inherent to the use of real-world evidence, including incomplete clinical variables (eg, tumor shrinkage for RECIST) and lack of a randomized standard of care/physician's choice arm.</p><p>In conclusion, overall, these findings suggest that the benefit of PARPi in patients with s<italic toggle="yes">BRCA</italic> and g<italic toggle="yes">PALB2</italic> mutations are comparable with those with g<italic toggle="yes">BRCA</italic>. Clinical trials investigating PARPi for patients beyond g<italic toggle="yes">BRCA</italic> are ongoing, and a scar-based marker such as HRDsig may play a complementary role in identifying patients who will have durable response to PARPi.</p></sec></body><back><fn-group content-type="presented-at"><title>PRIOR PRESENTATION</title><fn specific-use="presented-at" fn-type="presented-at"><p>Presented in part at ASCO Annual Meeting, Chicago, IL, June 4-8 2021.</p></fn></fn-group><fn-group><fn specific-use="equal" fn-type="equal"><label>*</label><p>F.B. and R.W.M. contributed equally to this work.</p></fn></fn-group><sec sec-type="data-availability"><title>DATA SHARING STATEMENT</title><p>The authors declare that all relevant aggregate data supporting the findings of this study are available within the article and its supplementary information files. In accordance with the Health Insurance Portability and Accountability Act, we do not have institutional review board approval or patient consent to share individualized patient genomic data, which contain potentially identifying or sensitive patient information and cannot be reported in a public data repository. Foundation Medicine is committed to collaborative data analysis and has well-established and widely used mechanisms by which qualified researchers can query our core genomic database of &gt;500,000 deidentified sequenced cancers. More information and mechanisms for data access can be obtained by contacting the corresponding author or the Foundation Medicine Data Governance Council at <email>data.governance.council@foundationmedicine.com</email>.</p></sec><sec sec-type="contributed"><title>AUTHOR CONTRIBUTIONS</title><p><bold>Conception and design:</bold> Felipe Batalini, Russell W. Madison, Ethan S. Sokol, Kuei-Ting Chen, Garrett M. Frampton, Alexa B. Schrock, Nadine M. Tung</p><p><bold>Collection and assembly of data:</bold> Dexter X. Jin, Dean C. Pavlick, Garrett M. Frampton</p><p><bold>Data analysis and interpretation:</bold> Felipe Batalini, Russell W. Madison, Ethan S. Sokol, Dexter X. Jin, Kuei-Ting Chen, Brennan Decker, Dean C. Pavlick, Garrett M. Frampton, Gerburg M. Wulf, Judy E. Garber, Geoffrey Oxnard, Alexa B. Schrock</p><p><bold>Manuscript writing:</bold> All authors</p><p><bold>Final approval of manuscript:</bold> All authors</p><p><bold>Accountable for all aspects of the work:</bold> All authors</p></sec><sec sec-type="COI-statement"><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ascopubs.org/po/author-center" ext-link-type="uri">ascopubs.org/po/author-center</ext-link>.</p><p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p><fn-group content-type="COI-statement"><fn id="con1" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Felipe Batalini</bold>
</p><p><bold>Consulting or Advisory Role:</bold> Curio Science, Illumina/Grail, Novartis, Daiichi Sankyo/Astra Zeneca, Merck, MDoutlook, Prova Health, OncLive/MJH Life Sciences, Stemline Therapeutics</p></fn><fn id="con2" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Russell W. Madison</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche</p></fn><fn id="con3" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Ethan S. Sokol</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche</p></fn><fn id="con4" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Dexter X. Jin</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche</p></fn><fn id="con5" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Kuei-Ting Chen</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche</p></fn><fn id="con6" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Brennan Decker</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche, Vaccitech</p><p><bold>Patents, Royalties, Other Intellectual Property:</bold> I am an inventor on numerous FMI-owned patent submissions related to research and development activities</p></fn><fn id="con7" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Dean C. Pavlick</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche</p></fn><fn id="con8" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Garrett M. Frampton</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Roche</p></fn><fn id="con9" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Gerburg M. Wulf</bold>
</p><p><bold>Stock and Other Ownership Interests:</bold> Selecta Biosciences</p><p><bold>Research Funding:</bold> Merck, GlaxoSmithKline (Inst), Genentech (Inst), Seagen (Inst)</p><p><bold>Patents, Royalties, Other Intellectual Property:</bold> Pin1 as a marker for abnormal cell growth Patent number: 8129131, Pin1 inhibitors (Inst)</p><p><bold>Open Payments Link:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/physician/453719" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/453719</ext-link></p></fn><fn id="con10" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Judy E. Garber</bold>
</p><p><bold>Consulting or Advisory Role:</bold> Novartis, Kronos Bio, GV20 Therapeutics, Belharra Therapeutics, Inc, Earli, Inc</p><p><bold>Research Funding:</bold> Novartis, Ambry Genetics, InVitae, Amgen</p><p><bold>Other Relationship:</bold> AACR, Diana Helis Henry Medical Foundation, James P. Wilmot Foundation, Adrienne Helis Malvin Medical Research Foundation, Breast Cancer Research Foundation, Facing our Risk of Cancer Empowered</p></fn><fn id="con11" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Geoffrey Oxnard</bold>
</p><p>This author is a member of the <italic toggle="yes">JCO Precision Oncology</italic> Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.</p><p><bold>Employment:</bold> Foundation Medicine, Loxo at Lilly</p><p><bold>Stock and Other Ownership Interests:</bold> Roche, Lilly</p></fn><fn id="con12" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Alexa B. Schrock</bold>
</p><p><bold>Employment:</bold> Foundation Medicine</p><p><bold>Stock and Other Ownership Interests:</bold> Foundation Medicine, Roche</p></fn><fn id="con13" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Nadine M. Tung</bold>
</p><p><bold>Consulting or Advisory Role:</bold> AstraZeneca</p><p><bold>Research Funding:</bold> AstraZeneca (Inst)</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></sec><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farmer</surname><given-names>H</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source><volume>434</volume>:<fpage>917</fpage>-<lpage>921</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15829967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature03445</pub-id></mixed-citation></ref><ref id="b2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelmon</surname><given-names>KA</given-names></name><name name-style="western"><surname>Tischkowitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>: <article-title>Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study</article-title>. <source>Lancet Oncol</source><volume>12</volume>:<fpage>852</fpage>-<lpage>861</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21862407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(11)70214-5</pub-id></mixed-citation></ref><ref id="b3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>M</given-names></name><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name><name name-style="western"><surname>Senkus</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</article-title>. <source>N Engl J Med</source><volume>377</volume>:<fpage>523</fpage>-<lpage>533</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28578601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1706450</pub-id></mixed-citation></ref><ref id="b4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Litton</surname><given-names>JK</given-names></name><name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name><name name-style="western"><surname>Ettl</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Talazoparib in patients with advanced breast cancer and a germline BRCA mutation</article-title>. <source>N Engl J Med</source><volume>379</volume>:<fpage>753</fpage>-<lpage>763</lpage>, <year>2018</year><pub-id pub-id-type="pmid">30110579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1802905</pub-id><pub-id pub-id-type="pmcid">PMC10600918</pub-id></mixed-citation></ref><ref id="b5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tutt</surname><given-names>ANJ</given-names></name><name name-style="western"><surname>Garber</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>: <article-title>Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>2394</fpage>-<lpage>2405</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34081848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2105215</pub-id><pub-id pub-id-type="pmcid">PMC9126186</pub-id></mixed-citation></ref><ref id="b6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>K</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>N</given-names></name><name name-style="western"><surname>Scambia</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>: <article-title>Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer</article-title>. <source>N Engl J Med</source><volume>379</volume>:<fpage>2495</fpage>-<lpage>2505</lpage>, <year>2018</year><pub-id pub-id-type="pmid">30345884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1810858</pub-id></mixed-citation></ref><ref id="b7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Oza</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lorusso</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>: <article-title>Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source><volume>390</volume>:<fpage>1949</fpage>-<lpage>1961</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28916367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)32440-6</pub-id><pub-id pub-id-type="pmcid">PMC5901715</pub-id></mixed-citation></ref><ref id="b8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Mart&#237;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Pothuri</surname><given-names>B</given-names></name><name name-style="western"><surname>Vergote</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>: <article-title>Niraparib in patients with newly diagnosed advanced ovarian cancer</article-title>. <source>N Engl J Med</source><volume>381</volume>:<fpage>2391</fpage>-<lpage>2402</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31562799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1910962</pub-id></mixed-citation></ref><ref id="b9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monk</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>: <article-title>ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer</article-title>. <source>Int J Gynecol Cancer</source><volume>31</volume>:<fpage>1589</fpage>-<lpage>1594</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34593565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ijgc-2021-002933</pub-id><pub-id pub-id-type="pmcid">PMC8666815</pub-id></mixed-citation></ref><ref id="b10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batalini</surname><given-names>F</given-names></name><name name-style="western"><surname>DaSilva</surname><given-names>LL</given-names></name><name name-style="western"><surname>Campoverde</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: A systematic review and meta-analysis</article-title>. <source>Chin Clin Oncol</source><volume>12</volume>:<fpage>21</fpage>, <year>2023</year><pub-id pub-id-type="pmid">37211773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/cco-22-114</pub-id></mixed-citation></ref><ref id="b11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>NM</given-names></name><name name-style="western"><surname>Robson</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ventz</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)</article-title>. <source>J Clin Oncol</source><volume>38</volume>, <year>2020</year> (<comment>suppl 15; abstr 1002</comment>)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.02151</pub-id><pub-id pub-id-type="pmid">33119476</pub-id></mixed-citation></ref><ref id="b12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K-T</given-names></name><name name-style="western"><surname>Madison</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-ribose) polymerase inhibitor response</article-title>. <source>JCO Precis Oncol</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ascopubs.org/doi/full/10.1200/PO.23.00093" ext-link-type="uri">10.1200/PO.23.00093</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.23.00093</pub-id><pub-id pub-id-type="pmid">37769224</pub-id></mixed-citation></ref><ref id="b13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frampton</surname><given-names>GM</given-names></name><name name-style="western"><surname>Fichtenholtz</surname><given-names>A</given-names></name><name name-style="western"><surname>Otto</surname><given-names>GA</given-names></name>, <etal>et al</etal></person-group>: <article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title>. <source>Nat Biotechnol</source><volume>31</volume>:<fpage>1023</fpage>-<lpage>1031</lpage>, <year>2013</year><pub-id pub-id-type="pmid">24142049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2696</pub-id><pub-id pub-id-type="pmcid">PMC5710001</pub-id></mixed-citation></ref><ref id="b14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>JX</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sanford</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal</article-title>. <source>PLoS Comput Biol</source><volume>14</volume>:<fpage>e1005965</fpage>, <year>2018</year><pub-id pub-id-type="pmid">29415044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1005965</pub-id><pub-id pub-id-type="pmcid">PMC5832436</pub-id></mixed-citation></ref><ref id="b15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokol</surname><given-names>ES</given-names></name><name name-style="western"><surname>Pavlick</surname><given-names>D</given-names></name><name name-style="western"><surname>Khiabanian</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>: <article-title>Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity</article-title>. <source>JCO Precis Oncol</source><volume>4</volume>:<fpage>442</fpage>-<lpage>465</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32903788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.19.00345</pub-id><pub-id pub-id-type="pmcid">PMC7446440</pub-id></mixed-citation></ref><ref id="b16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandrov</surname><given-names>LB</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Haradhvala</surname><given-names>NJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>The repertoire of mutational signatures in human cancer</article-title>. <source>Nature</source><volume>578</volume>:<fpage>94</fpage>-<lpage>101</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32025018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-1943-3</pub-id><pub-id pub-id-type="pmcid">PMC7054213</pub-id></mixed-citation></ref><ref id="b17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkevich</surname><given-names>V</given-names></name><name name-style="western"><surname>Timms</surname><given-names>KM</given-names></name><name name-style="western"><surname>Hennessy</surname><given-names>BT</given-names></name>, <etal>et al</etal></person-group>: <article-title>Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer</article-title>. <source>Br J Cancer</source><volume>107</volume>:<fpage>1776</fpage>-<lpage>1782</lpage>, <year>2012</year><pub-id pub-id-type="pmid">23047548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2012.451</pub-id><pub-id pub-id-type="pmcid">PMC3493866</pub-id></mixed-citation></ref><ref id="b18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkbak</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name>, <etal>et al</etal></person-group>: <article-title>Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents</article-title>. <source>Cancer Discov</source><volume>2</volume>:<fpage>366</fpage>-<lpage>375</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22576213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-11-0206</pub-id><pub-id pub-id-type="pmcid">PMC3806629</pub-id></mixed-citation></ref><ref id="b19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popova</surname><given-names>T</given-names></name><name name-style="western"><surname>Mani&#233;</surname><given-names>E</given-names></name><name name-style="western"><surname>Rieunier</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>: <article-title>Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation</article-title>. <source>Cancer Res</source><volume>72</volume>:<fpage>5454</fpage>-<lpage>5462</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22933060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-12-1470</pub-id></mixed-citation></ref><ref id="b20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timms</surname><given-names>KM</given-names></name><name name-style="western"><surname>Abkevich</surname><given-names>V</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes</article-title>. <source>Breast Cancer Res</source><volume>16</volume>:<fpage>475</fpage>, <year>2014</year><pub-id pub-id-type="pmid">25475740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-014-0475-x</pub-id><pub-id pub-id-type="pmcid">PMC4308910</pub-id></mixed-citation></ref><ref id="b21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singal</surname><given-names>G</given-names></name><name name-style="western"><surname>Miller</surname><given-names>PG</given-names></name><name name-style="western"><surname>Agarwala</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>: <article-title>Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database</article-title>. <source>JAMA</source><volume>321</volume>:<fpage>1391</fpage>-<lpage>1399</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30964529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.3241</pub-id><pub-id pub-id-type="pmcid">PMC6459115</pub-id></mixed-citation></ref><ref id="b22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruber</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Afghahi</surname><given-names>A</given-names></name><name name-style="western"><surname>Timms</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>: <article-title>A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes</article-title>. <source>Nat Cancer</source><volume>3</volume>:<fpage>1181</fpage>-<lpage>1191</lpage>, <year>2022</year><pub-id pub-id-type="pmid">36253484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-022-00439-1</pub-id><pub-id pub-id-type="pmcid">PMC9586861</pub-id></mixed-citation></ref><ref id="b23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>ME</given-names></name><name name-style="western"><surname>Tung</surname><given-names>N</given-names></name><name name-style="western"><surname>Conte</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>: <article-title>OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician&#8217;s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title>. <source>Ann Oncol</source><volume>30</volume>:<fpage>558</fpage>-<lpage>566</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30689707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz012</pub-id><pub-id pub-id-type="pmcid">PMC6503629</pub-id></mixed-citation></ref><ref id="b24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batalini</surname><given-names>F</given-names></name><name name-style="western"><surname>Gulhan</surname><given-names>DC</given-names></name><name name-style="western"><surname>Mao</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>: <article-title>Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers</article-title>. <source>Clin Cancer Res</source><volume>28</volume>:<fpage>4714</fpage>-<lpage>4723</lpage>, <year>2022</year><pub-id pub-id-type="pmid">36048535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-0749</pub-id><pub-id pub-id-type="pmcid">PMC9623231</pub-id></mixed-citation></ref><ref id="b25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menezes</surname><given-names>MCS</given-names></name><name name-style="western"><surname>Raheem</surname><given-names>F</given-names></name><name name-style="western"><surname>Mina</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>PARP inhibitors for breast cancer: Germline BRCA1/2 and beyond</article-title>. <source>Cancers (Basel)</source><volume>14</volume>:<fpage>4332</fpage>, <year>2022</year><pub-id pub-id-type="pmid">36077867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14174332</pub-id><pub-id pub-id-type="pmcid">PMC9454726</pub-id></mixed-citation></ref><ref id="b26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Sonzogni</surname><given-names>O</given-names></name>, <etal>et al</etal></person-group>: <article-title>PARP-inhibition reprograms macrophages toward an anti-tumor phenotype</article-title>. <source>Cell Rep</source><volume>41</volume>:<fpage>111462</fpage>, <year>2022</year><pub-id pub-id-type="pmid">36223740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2022.111462</pub-id><pub-id pub-id-type="pmcid">PMC9727835</pub-id></mixed-citation></ref><ref id="b27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polak</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Braunstein</surname><given-names>LZ</given-names></name>, <etal>et al</etal></person-group>: <article-title>A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer</article-title>. <source>Nat Genet</source><volume>49</volume>:<fpage>1476</fpage>-<lpage>1486</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28825726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3934</pub-id><pub-id pub-id-type="pmcid">PMC7376751</pub-id></mixed-citation></ref><ref id="b28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulhan</surname><given-names>DC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JJK</given-names></name><name name-style="western"><surname>Melloni</surname><given-names>GEM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Detecting the mutational signature of homologous recombination deficiency in clinical samples</article-title>. <source>Nat Genet</source><volume>51</volume>:<fpage>912</fpage>-<lpage>919</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30988514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0390-2</pub-id></mixed-citation></ref><ref id="b29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Wijngaart</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoes</surname><given-names>LR</given-names></name><name name-style="western"><surname>van Berge Henegouwen</surname><given-names>JM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Patients with biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types</article-title>. <source>Clin Cancer Res</source><volume>27</volume>:<fpage>6106</fpage>-<lpage>6114</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34475104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-1104</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>